Application of Glycyrrhiza inflata polysaccharide in preparing drugs for treating and / or preventing liver cancer

Abstract

The present invention discloses the application of Glycyrrhiza inflata polysaccharide in the preparation of drugs for treating and / or preventing liver cancer, belonging to the technical field of vaccine adjuvants. The crude Glycyrrhiza inflata polysaccharide GiP and the homogeneous Glycyrrhiza inflata polysaccharide GiP-B1 provided by the present invention have relatively significant antitumor activities when acting synergistically with dendritic cells (DCs). At the same time, the crude Glycyrrhiza inflata polysaccharide GiP and the homogeneous Glycyrrhiza inflata polysaccharide GiP-B1 can also promote the maturation of the phenotype of bone marrow-derived DCs in normal mice and improve the antigen presentation function of DCs. The DC vaccine loaded with tumor antigen prepared by the present invention can promote the maturation of DCs, up-regulate the expression of surface marker molecules of DCs, and has a certain immunotherapeutic effect on H22 liver cancer-bearing mice. The Glycyrrhiza inflata polysaccharide can be used as a DC vaccine adjuvant for the preparation of drugs for treating and / or preventing liver cancer.

Description

Technical Field

[0001] The present invention relates to the technical field of vaccine adjuvants, and particularly to the application of Glycyrrhiza inflata polysaccharide in the preparation of a medicament for treating and / or preventing liver cancer. Background Art

[0002] The incidence of liver cancer ranks sixth among global malignant tumors, and the fatality rate ranks third. The traditional treatment methods for liver cancer include surgery, chemotherapy or radiotherapy. Although they are curative treatments, the tumor recurrence rate is still very high. Tumor immunotherapy mainly includes immune checkpoint inhibitors, cellular immunotherapy, exosome immunotherapy and other novel therapies, which enhance the ability of the immune system to prevent and combat tumors by activating the individual's immune system, selectively targeting tumor antigens, and guiding immune cells to kill tumor cells.

[0003] Dendritic cells (DCs) are the most powerful antigen-presenting cells in the body's immune system and are the core of antigen-specific immunity and tolerance initiation. They process and present antigens to the innate and adaptive immune systems through major histocompatibility complex I (MHC-I) and MHC-II molecules and play a key role in the connection between the innate and adaptive immune systems. Under normal circumstances, DCs exist in an immature state, have strong antigen phagocytosis ability, and have a low expression level of co-stimulatory molecules on the cell surface, playing an important role in maintaining immune tolerance in the body. Once the body is stimulated by pathogenic microorganisms or other stimuli, DCs can rapidly upregulate the expression of co-stimulatory molecules on their surface, such as CD80, CD86 and MHC-II, and at the same time acquire migratory ability, carry signals from pathogenic microorganisms to lymph nodes and activate T cells.

[0004] DC-based vaccine therapy is considered a classic cancer immunotherapy method because it can activate the immune system, enhance tumor-specific cytotoxic responses and kill tumor cells. DC vaccines are therapeutic cancer vaccines. Generally, immature DCs (imDCs) are isolated from the peripheral blood of tumor patients or healthy people, matured by tumor antigen stimulation, and then transfused into the patient's body for treatment, which can activate cytotoxic T lymphocytes (CTLs) targeting tumor cells in the patient's body and play an anti-tumor role. In recent years, DC vaccines containing antigens are a safe and promising therapy for treating tumors. This DC-based tumor immunotherapy has been tested in clinical trials for various tumors such as breast cancer, multiple myeloma, prostate cancer, renal cell carcinoma, malignant melanoma, colorectal cancer and non-small cell lung cancer.

[0005] However, with the continuous in-depth research on immunotherapy, it is found that the problems existing in the development of DC vaccines are that the immunogenicity of tumor antigens is weak, the maturation and function of DCs in tumor tissues and peripheral blood are inhibited, and it is difficult to trigger the body's innate immune response. Therefore, it is necessary to add vaccine adjuvants to promote DC maturation and enhance the immunogenicity of tumor antigens. Some adjuvants have been approved for human vaccines, including MF59, AS03, AS04, CpG ODN, and AS01, but the issues of effectiveness and safety still pose challenges to the development of new adjuvants. Thus, there is a need to develop new safe and effective adjuvants. Summary of the Invention

[0006] The object of the present invention is to provide the application of Glycyrrhiza inflata polysaccharide in the preparation of drugs for the treatment and / or prevention of liver cancer, so as to solve the problems existing in the above-mentioned prior art.

[0007] To achieve the above object, the present invention provides the following solutions:

[0008] The present invention provides the application of Glycyrrhiza inflata polysaccharide in the preparation of drugs for the treatment and / or prevention of liver cancer.

[0009] Preferably, the drug includes a vaccine.

[0010] Preferably, the vaccine is a dendritic cell vaccine; the Glycyrrhiza inflata polysaccharide is a vaccine adjuvant.

[0011] Preferably, the Glycyrrhiza inflata polysaccharide is at least one of Glycyrrhiza inflata crude polysaccharide GiP or Glycyrrhiza inflata homogeneous polysaccharide GiP-B1.

[0012] Preferably, the dosage of Glycyrrhiza inflata is 100 μg / mL.

[0013] Preferably, the relative molecular weight of the Glycyrrhiza inflata homogeneous polysaccharide GiP-B1 is not less than 2.0×10 6 Da.

[0014] Preferably, the uronic acid content of the Glycyrrhiza inflata homogeneous polysaccharide GiP-B1 is 16.8%.

[0015] The present invention also provides a dendritic cell vaccine for the treatment and / or prevention of liver cancer, and the vaccine uses Glycyrrhiza inflata polysaccharide as an adjuvant.

[0016] The present invention discloses the following technical effects:

[0017] When the crude polysaccharide GiP of Glycyrrhiza inflata and the homogeneous polysaccharide GiP-B1 of Glycyrrhiza inflata cooperate with DC, they show significant antitumor activity. At the same time, the crude polysaccharide GiP of Glycyrrhiza inflata and the homogeneous polysaccharide GiP-B1 of Glycyrrhiza inflata can also promote the maturation of the phenotype of bone marrow-derived DC in normal mice and improve the antigen presentation function of DC. The DC vaccine prepared in the present invention by loading tumor antigens with Glycyrrhiza inflata polysaccharide can promote the maturation of DC, up-regulate the expression of surface marker molecules of DC, and has a certain immunotherapeutic effect on H22 liver cancer-bearing mice. Glycyrrhiza inflata polysaccharide can be used as an adjuvant for DC vaccine to prepare drugs for the treatment and / or prevention of liver cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the drawings required in the embodiments. Obviously, the drawings in the following description are only some embodiments of the present invention. For those of ordinary skill in the art, without creative efforts, other drawings can also be obtained based on these drawings.

[0019] Figure 1 are the morphological changes during the culture of BMDC (magnification ×200); among them, A: the 2nd day; B: the 3rd day; C: the 4th day; D: the 5th day;

[0020] Figure 2 are the morphologies of DC vaccines in each group (magnification ×200); among them, A: DC group; B: TNF-α group; C: GiP group; D: GiP-B1 group;

[0021] Figure 3 is the expression of surface marker molecules of the DC vaccine assisted by Glycyrrhiza inflata polysaccharide;

[0022] Figure 4 are the changes in the body weights of tumor-bearing mice in each group during immunotherapy compared with the model group (vs. model group), a P < 0.05, b P < 0.01;

[0023] Figure 5 are the changes in the tumor volumes of tumor-bearing mice in each group during immunotherapy. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0024] The various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but should be understood as a more detailed description of certain aspects, characteristics, and implementation schemes of the present invention.

[0025] It should be understood that the terms used in the present invention are only for describing specific embodiments and are not intended to limit the present invention. Additionally, for the numerical ranges in the present invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Each intermediate value within any stated value or stated range, as well as each smaller range between any other stated value or intermediate value within the stated range, is also included in the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0026] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although the present invention only describes preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials related to the documents. In case of conflict with any incorporated document, the content of this specification shall prevail.

[0027] Without departing from the scope or spirit of the present invention, various improvements and changes can be made to the specific embodiments of the present invention specification, which are obvious to those skilled in the art. Other embodiments obtained from the specification of the present invention are obvious to those skilled in the art. The specification and examples of this application are merely exemplary.

[0028] Regarding the use of "comprising", "including", "having", "containing", etc. herein, they are all open-ended terms, meaning including but not limited to.

[0029] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are all purchased from commercial channels or have been publicly disclosed.

[0030] Example 1

[0031] 1. Cultivation of H22 mouse hepatoma cells

[0032] 1) Cell resuscitation: Take out the H22 mouse hepatoma cells from the liquid nitrogen tank and put them into a PE glove, quickly place them in a 37°C constant temperature water bath, quickly shake the cryopreservation tube to dissolve it quickly (about 1 min). After the cryopreservation solution melts, quickly add it to a centrifuge tube containing 10 times the volume of normal complete culture medium, centrifuge at 1000 rpm for 5 min, discard the supernatant, resuspend the cells with 2 mL of complete culture medium, transfer them into a 10 cm culture dish, make up the cell culture medium to 10 mL, and place it in a 37°C, 5% CO2 cell culture incubator for continuous culture, changing the medium once every 2 - 3 days.

[0033] 2) Cell medium change: H22 cells are suspension cells. Use a pipette to aspirate the culture medium and gently pipette to mix the cells evenly. Collect the cell suspension into a sterile centrifuge tube, centrifuge at 1200 rpm for 5 min, discard the supernatant, add fresh complete medium, pipette to mix the cells evenly, transfer them into a 10-cm culture dish, and place them in a cell incubator at 37°C and 5% CO2 for continuous culture. Change the medium once every 2 - 3 days.

[0034] 2. Preparation of H22 tumor cell lysate

[0035] Collect H22 cells in the logarithmic growth phase, centrifuge at 1200 rpm for 5 min, discard the supernatant, adjust the density of the cell suspension to 1×10 7 cells / mL, transfer them into a 5-mL cryotube, place them in a liquid nitrogen tank for 30 min, take them out and dissolve them in a 37°C water bath for 5 min. Repeat the above steps and freeze-thaw 5 times to obtain H22 cell lysate. Centrifuge the H22 tumor cell lysate at 1500 rpm for 5 min, collect the supernatant, filter it through a 0.22-μm microporous filter, and store it in liquid nitrogen for later use. Take an appropriate amount of the filtered H22 cell lysate and measure the protein content using a BCA kit.

[0036] The protein concentration of the tumor cell lysate measured by the BCA method is 11.33 mg / mL. Use 25 μg / mL of TCL to load DC and prepare DC vaccine.

[0037] 3. Isolation and culture of mouse bone marrow-derived DC

[0038] Put the femurs and tibias of C57BL / 6 male mice in a culture dish containing RPMI 1640 basal medium. Cut off both ends of the femur and tibia, use a 1-mL syringe to aspirate serum-free RPMI 1640 basal medium, insert the needle into the bone marrow cavity from both ends of the bone, and repeatedly rinse the bone marrow into the culture dish until the bone marrow cavity becomes completely white; use a 1-mL pipette to pipette and collect the bone marrow suspension, filter it through a 70-μm sterile cell filter, transfer it to a sterile centrifuge tube, centrifuge at 1200 rpm for 5 min, discard the supernatant, then resuspend it with 3 mL of RPMI 1640, centrifuge at 1200 rpm for 5 min, discard the supernatant, resuspend it with the complete medium for mouse bone marrow-derived dendritic cells, and transfer it to a 25-cm 2 culture flask, and culture it in a cell incubator at 37°C and 5% CO2. After 48 h, change the medium in full volume and remove the non-adherent cells for continuous culture; on the 4th day of culture, change the medium in half volume; on the 5th day, it is the immature mouse bone marrow-derived dendritic cells.

[0039] 4. Preparation of liver cancer dendritic cell vaccine

[0040] BMDC cultured until the 5th day, after counting, place 5×10 5Cells were seeded in six-well plates and divided into Control, DC, TNF-α, GiP, and GiP-B1 groups. In the Control group, neither TCL nor adjuvant was added; in the DC group, only TCL was added without adjuvant; in the TNF-α group, TCL and the cytokine TNF-α as adjuvant were added; in the GiP group, TCL and the crude polysaccharide GiP from Glycyrrhiza inflata Bat. as adjuvant were added; in the GiP-B1 group, TCL and the homogeneous polysaccharide GiP-B1 from Glycyrrhiza inflata Bat. as adjuvant were added. Therefore, except for the Control group, H22 liver cancer cell lysate was added to each well to a final concentration of 25 μg / mL, and the plates were incubated in a 37 °C cell culture incubator with 5% CO2 for 12 h. Except for the Control and DC groups, rmTNF-α (20 ng / mL), GiP (100 μg / mL), and GiP-B1 (100 μg / mL) were added to the TNF-α, GiP, and GiP-B1 groups, respectively. After further incubation for 48 h, DC vaccines loaded with tumor antigens were obtained, and the morphology of DC vaccines in each group was observed and recorded using a fluorescence inverted microscope.

[0041] On the first day of BMDC culture, most cells in the culture flask were round. The cells were continuously incubated statically without moving the cells. On the second day, the medium was completely changed, and non-adherent cells were discarded. Only a small number of single DCs were observed under the microscope, and DCs growing in colonies were occasionally seen. On the third day, the number of suspended cells gradually increased, the number of DCs with short "burr" - like protrusions increased, and the number of DC colonies increased. On the fourth day, a large number of suspended cells were observed under the microscope, the number of DCs increased, and they showed a typical colony growth state. On the fifth day, most of the colony - growing cells had short "burr" - like protrusions, which were typical imDCs. imDCs were sensitized with antigens and stimulated with adjuvants to become mDCs. Compared with imDCs, the "burr" - like protrusions of mDCs were significantly longer. Compared with the Control and DC groups, the protrusions in the TNF-α, GiP, and GiP-B1 groups were even longer. The DC vaccines in each group showed colony growth, which was the typical morphology of mDCs (as Figure 1 、 2 shown).

[0042] 5. Detection of the maturation degree of DC vaccines by flow cytometry

[0043] The suspended and semi - adherent cells of DC vaccines in each group were collected in 15 mL centrifuge tubes, centrifuged, and the supernatant was discarded. The cell pellet was washed twice with 1 mL of pre - cooled PBS buffer, and then the cells were resuspended in 100 μL of PBS. 2 μL of each of the flow - cytometry antibodies anti - mouse FITC - CD11c, FITC - CD80, PE - CD86, and PE - MHC - II were added, and the cells were incubated in the dark at 4 °C for 30 min. After the reaction was completed, the unbound antibodies were washed away with 1 mL of PBS. Finally, the cells were resuspended in 500 μL of PBS, and the cell suspension was passed through a 300 - mesh nylon sieve into a flow - cytometry tube to form a single - cell suspension and prevent cell clumps from blocking the pipeline of the flow - cytometry detector. The number of cells in each flow - cytometry tube should not be less than 1×106 cells, and the expression of the corresponding antibody was detected by flow cytometry. The detection results are shown in Table 1.

[0044] Table 1 Expression of surface marker molecules of DC vaccine assisted by Glycyrrhiza inflata polysaccharide (%, n = 3, )

[0045]

[0046]

[0047] Note: Compared with the blank control group, * indicates significant difference P < 0.05, ** indicates extremely significant difference P < 0.01; compared with the DC group, ▲ indicates significant difference P < 0.05, ▲▲ indicates extremely significant difference P < 0.01.

[0048] On the 8th day of culturing DCs in each group, the expression of cell surface marker molecules of DCs was detected by flow cytometry. CD11c is a marker molecule for identifying the purity of DCs; CD80, CD86, and MHC-II are surface marker molecules for identifying DC maturation. CD80 and CD86 can promote co-stimulatory signals to activate T cell responses; MHC-II presents peptides from exogenous proteins to CD4+ T cells. The expression levels of CD80, CD86, and MHC-II in the DC vaccines of each group compared with the Control group (as shown in Table 1) showed statistically significant differences (P < 0.05), indicating that loading with hepatoma cell antigens can stimulate DC maturation; compared with the DC group, the differences were statistically significant (P < 0.05), indicating that the adjuvant Glycyrrhiza inflata polysaccharide can effectively stimulate DC maturation. Comparing the crude polysaccharide GiP of Glycyrrhiza inflata with the homogeneous polysaccharide GiP-B1, the expression levels of CD80, CD86, and MHC-II in GiP-B1 were higher than those in GiP, and among them, the difference in MHC-II between the two groups was statistically significant (P < 0.05); the differences in CD80 and CD86 were not statistically significant (P > 0.05).

[0049] Example 2

[0050] 1 Immunotherapeutic effect of DC vaccine assisted by Glycyrrhiza inflata polysaccharide on H22 hepatoma-bearing mice

[0051] 1.1 Establishment and grouping of H22 hepatoma-bearing mouse models

[0052] H22 cells in the logarithmic growth phase were collected and resuspended with PBS to adjust the cell density to 1×10 7 cells·mL -1 . Then, 0.2 mL of the cell suspension was injected into the abdominal cavity of healthy KM female mice. Five days after injection, ascites was aspirated under sterile conditions and the concentration was adjusted to 1×10 7 cells·mL -1, Inject the cell suspension subcutaneously into the right axilla of mice after 7 days of adaptive feeding. If a tumor appears at the inoculation site on the 7th day, the modeling is successful. According to the tumor volume, randomly divide the mice into 6 groups: the model group, the positive group, the DC group, the TNF-α group, the GiP group, and the GiP-B1 group.

[0053] 1.2 DC vaccine assisted by Glycyrrhiza inflata polysaccharide for treating H22 hepatocarcinoma-bearing mice

[0054] Take the prepared DC vaccine above and administer it by intraperitoneal injection. Inject 200 μL (5×10 5 cells) of the corresponding DCs vaccine to each group of tumor-bearing mice. The model group is injected with PBS, and the positive group is injected with oxaliplatin (10 mg·kg -1 ). Treatment starts on the 7th day after H22 cell inoculation, and is carried out once every 7 days for a total of 2 times.

[0055] 1.3 Effects of DC vaccine assisted by Glycyrrhiza inflata polysaccharide on the growth status, body weight, tumor weight, and organ indices of H22 hepatocarcinoma-bearing mice

[0056] Since the first administration, observe the food and water intake, activity level, hair, etc. of the mice. Measure the tumor volume and mouse body weight every 2 days. After 12 hours of fasting 5 days after the last administration, weigh each group of mice, collect blood by eye socket puncture, sacrifice the mice by cervical dislocation, dissect the axillary tumors of the mice, take out the spleen, thymus, and liver tissues, immediately weigh and record, and calculate the tumor inhibition rate and each organ index. Calculate according to the following formulas:

[0057] Tumor volume = A × B 2 × 0.5 (A: long diameter of the tumor, B: short diameter of the tumor)

[0058] Tumor inhibition rate % = (average tumor weight of the model group - average tumor weight of the drug administration group) / average tumor weight of the model group × 100%

[0059] Liver index = liver mass (mg) / mouse body weight (g);

[0060] Spleen index = spleen mass (mg) / mouse body weight (g);

[0061] Thymus index = thymus mass (mg) / mouse body weight (g).

[0062] 1.4 Effects of DC vaccine assisted by Glycyrrhiza inflata polysaccharide on cytokines in the serum of H22 hepatocarcinoma-bearing mice

[0063] Collect blood from the eye sockets of each group of mice. After standing at room temperature for 4 hours, centrifuge at 3000 rpm for 10 minutes to collect the serum. Measure the contents of IL-12 (P70), IFN-γ, IL-4, and IL-10 cytokines respectively according to the instructions of the Elisa kit.

[0064] 1.5 Statistical analysis

[0065] The data results were expressed as mean ± standard deviation , and one-way ANOVA or independent samples t-test was used for data comparison. A P value < 0.05 was considered statistically significant. The results of FCM detection were analyzed using Flowjo 10.8.1 software, and the results of immunohistochemistry were analyzed using Fiji software.

[0066] 2 Results

[0067] 2.1 Effects of DC vaccine assisted by Glycyrrhiza inflata polysaccharide on the growth status and body weight of H22 hepatoma-bearing mice

[0068] As Figure 4 shown, after tumor-bearing, the activity status, spirit, and food intake of mice in each group were almost the same as before inoculation; on the 7th day, tumor tissues with a diameter of about 10 mm could be seen under the armpits of mice in each group. Three days after administration, the mice in the positive control group were significantly seen with rapid breathing and poor mental state, and weight loss (P < 0.05); compared with the model group, the mice in the TNF-α, GiP, GiP-B1, and DC groups had better diet and mental state, and there were no obvious changes compared with subcutaneous tumor-bearing and before administration, and the body weights all increased.

[0069] 2.2 Effects of DC vaccine assisted by Glycyrrhiza inflata polysaccharide on tumor weight, tumor volume change, and tumor inhibition rate of H22 hepatoma-bearing mice

[0070] As shown in Table 2 and Figure 5 visible, compared with the model group, the tumor volumes of mice in the positive control group, TNF-α, and GiP-B1 groups all decreased, and the differences were statistically significant (P < 0.05); compared with the model group, the tumor weights of mice in the positive control group, TNF-α, DC, and GiP-B1 groups all decreased, and the differences were statistically significant (P < 0.05); it is suggested that the DC vaccines in each group have an inhibitory effect on the growth of tumors in H22 tumor-bearing mice.

[0071] Table 2 Effects of immunotherapy on tumor weight, tumor volume, and tumor inhibition rate of tumor-bearing mice

[0072]

[0073] Note: Compared with the model group (vs. model group), a P < 0.05, b P < 0.01.

[0074] 2.3 Effects of DC vaccine assisted by Glycyrrhiza inflata polysaccharide on the organ index of H22 hepatoma-bearing mice

[0075] As shown in Table 3, compared with the model group, the thymus indices of the TNF-α, DC, GiP, and GiP-B1 groups were significantly increased, with statistically significant differences (P<0.05); compared with the model group, the spleen indices of the positive group, TNF-α, DC, and GiP groups were significantly increased, with statistically significant differences (P<0.05); compared with the model group, the liver indices of the positive group, DC, and GiP groups were significantly increased, with statistically significant differences (P<0.05). The DC vaccine assisted by Glycyrrhiza inflata polysaccharide increased the thymus index and spleen index, suggesting that the DC vaccine assisted by Glycyrrhiza inflata polysaccharide has the effect of improving the body's immune function.

[0076] Table 3 Effects of immunotherapy on the organ indices of tumor-bearing mice (mg·g -1 , )

[0077]

[0078] Note: Compared with the model group (vs.model group), a P<0.05, b P<0.01.

[0079] 3.4 Effects of the DC vaccine assisted by Glycyrrhiza inflata polysaccharide on the cytokine content in the serum of H22 hepatoma-bearing mice

[0080] As shown in Table 4, compared with the model group, the contents of IL-12(P70) and IFN-γ in the positive group, DC, GiP, and GiP-B1 groups were significantly increased, with statistically significant differences (P<0.05); the content of IL-10 in each group decreased, with statistically significant differences (P<0.01); the content of IL-4 in each group decreased, and there were statistically significant differences in the GiP and GiP-B1 groups (P<0.05). The results suggest that the DC vaccine assisted by Glycyrrhiza inflata polysaccharide can regulate the Th1 / Th2 imbalance in tumor-bearing mice to shift towards Th1-mediated cellular immunity, enhance the body's cellular immune function, and exert an anti-tumor effect through the cellular immune pathway.

[0081] Table 4 Effects of immunotherapy on the cytokine content in tumor-bearing mice (pg·mL -1 , )

[0082]

[0083] Note: Compared with the model group (vs.model group), a P<0.05, b P<0.01.

[0084] The embodiments described above are only descriptions of the preferred embodiments of the present invention and do not limit the scope of the present invention. Without departing from the spirit of the present invention's design, various deformations and improvements made by those of ordinary skill in the art to the technical solutions of the present invention shall fall within the protection scope determined by the claims of the present invention.

Claims

1. Use of Glycyrrhiza inflata polysaccharide in the preparation of a drug for treating and / or preventing liver cancer, characterized in that, The drug is a vaccine; The vaccine is a dendritic cell vaccine; the polysaccharide of Glycyrrhiza inflata Bat. is a vaccine adjuvant; The polysaccharide from Glycyrrhiza inflata Bat. is the homogeneous polysaccharide GiP-B1 of Glycyrrhiza inflata Bat.; the relative molecular weight of the homogeneous polysaccharide GiP-B1 of Glycyrrhiza inflata Bat. is not less than 2.0×10 6 Da; the uronic acid content of the homogeneous polysaccharide GiP-B1 of Glycyrrhiza inflata Bat. is 16.8%.

2. A dendritic cell vaccine for treating and / or preventing liver cancer, characterized in that, The vaccine uses the polysaccharide of Glycyrrhiza inflata Bat. as an adjuvant; The Glycyrrhiza inflata polysaccharide is the Glycyrrhiza inflata homogeneous polysaccharide GiP-B1; the relative molecular weight of the Glycyrrhiza inflata homogeneous polysaccharide GiP-B1 is not less than 2.0×10 6 Da; the uronic acid content of the Glycyrrhiza inflata homogeneous polysaccharide GiP-B1 is 16.8%.

Images